Pharma’s increasing early engagement with small biotechs has been one of the themes of the industry in the last decade as companies prepare for a shift towards personalized medicines.
Nobody knows exactly who will drive the change, and how the resulting wave of new treatments will be commercialized. But linking up with external researchers seems a good bet – judging by the approach being adopted by drug companies of all sizes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze